Stock of the Day: Cytosorbents Corp’s (NASDAQ:CTSO) Sentiment is 1.78

November 21, 2016 - By Richard Conner   ·   0 Comments

Stock of the Day: Cytosorbents Corp's (NASDAQ:CTSO) Sentiment is 1.78

Sentiment for Cytosorbents Corp (NASDAQ:CTSO)

Cytosorbents Corp (NASDAQ:CTSO) institutional sentiment increased to 1.78 in Q2 2016. Its up 0.99, from 0.79 in 2016Q1. The ratio is positive, as 11 investment managers started new and increased stock positions, while 14 sold and reduced their positions in Cytosorbents Corp. The investment managers in our partner’s database now possess: 1.36 million shares, down from 1.40 million shares in 2016Q1. Also, the number of investment managers holding Cytosorbents Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 7 Increased: 7 New Position: 4.

CytoSorbents Corporation is a critical care focused immunotherapy company. The company has a market cap of $128.11 million. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. It currently has negative earnings. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

About 36,973 shares traded hands. Cytosorbents Corp (NASDAQ:CTSO) has risen 23.81% since April 19, 2016 and is uptrending. It has outperformed by 19.95% the S&P500.

According to Zacks Investment Research, “CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company’s product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.”

Fortaleza Asset Management Inc holds 0.07% of its portfolio in Cytosorbents Corp for 19,625 shares. Skylands Capital Llc owns 48,350 shares or 0.04% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 6,540 shares. The New York-based Bank Of New York Mellon Corp has invested 0% in the stock. Barclays Plc, a United Kingdom-based fund reported 4 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 2 buys, and 0 sales for $39,090 net activity.

Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage

Ratings analysis reveals 100% of CytoSorbents’s analysts are positive. Out of 4 Wall Street analysts rating CytoSorbents, 4 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8 while the high is $13.0. The stock’s average target of $10.75 is 107.53% above today’s ($5.18) share price. CTSO was included in 4 notes of analysts from October 29, 2015. The company was initiated on Friday, October 7 by B. Riley & Co. The stock of Cytosorbents Corp (NASDAQ:CTSO) has “Buy” rating given on Tuesday, May 24 by Maxim Group. The firm has “Buy” rating by Aegis Capital given on Wednesday, October 26. WBB Securities upgraded it to “Buy” rating and $13.0 target price in Thursday, October 29 report.

CTSO Company Profile

CytoSorbents Corporation, incorporated on April 25, 2002, is a critical care focused immunotherapy company. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.

More important recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Marketwatch.com which released: “Cytosorbents Corp.” on April 21, 2011, also Prnewswire.com published article titled: “CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment …”, Prnewswire.com published: “CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL” on September 08, 2016. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) was released by: Fool.com and their article: “Why Cytosorbents Corp Shares Burst Today” with publication date: April 01, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Richard Conner


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>